Lv1
66 积分 2024-06-21 加入
Research progress of STAT3-based dual inhibitors for cancer therapy
15天前
已完结
Targeting cancer with small molecule pan-KRAS degraders
17天前
已完结
Next-Generation Anti-IL-17 Agents for Psoriatic Disease: A Pipeline Review
1个月前
已完结
PP2A-B55: substrates and regulators in the control of cellular functions
1个月前
已完结
Abstract C163: KRAS alterations combined with TP53 mutations as novel synthetic lethal genomic lesions for PKMYT1 inhibition
1个月前
已关闭
Discovery and biological evaluation of 1-{2,7-diazaspiro[3.5]nonan-2-yl}prop-2-en-1-one derivatives as covalent inhibitors of KRAS G12C with favorable metabolic stability and anti-tumor activity
1个月前
已完结
Discovery of ASP6918, a KRAS G12C inhibitor: Synthesis and structure–activity relationships of 1-{2,7-diazaspiro[3.5]non-2-yl}prop-2-en-1-one derivatives as covalent inhibitors with good potency and oral activity for the treatment of solid tumors
1个月前
已完结
Discovery of tricyclic PARP7 inhibitors with high potency, selectivity, and oral bioavailability
1个月前
已完结
Industry perspective on the nonclinical safety assessment of heterobifunctional degraders
2个月前
已完结
Discovery of the First Potent, Selective, and In Vivo Efficacious Polo-like Kinase 4 Proteolysis Targeting Chimera Degrader for the Treatment of TRIM37-Amplified Breast Cancer
2个月前
已完结
皖公网安备34019202002308
